Free Newsletter
Two new diabetes drug targets identified
Scientists at Penn and Howard Hughes Medical Institute believe that their investigation of the role fat metabolism plays in the development of Type 2 diabetes has pointed to a new drug target. Their focus is a protein that plays a role in fat metabolism. The protein Akt2/PKB prevents fat metabolism by adding a phosphate group to PGC-1a, which is needed to trigger the genes needed for fat metabolism. Both PGC-1a and Akt2/PKB are good targets for new drug development, according to the researchers. The lead author is Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Diabetes and Metabolic Diseases at Penn and an Investigator of the Howard Hughes Medical Institute.
- read the report
Related Articles:
Diabetes market in flux as FDA mandates new warnings. Report
Diabetes prevention spurs development programs. Report
Transplants offer possible new cure for diabetes. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
